German Health Insurance: Rising Costs, Higher Contributions & Executive Pay

The German statutory health insurance system (GKV) is facing mounting financial pressure, with rising healthcare costs outpacing increases in contributions. Preliminary figures released by the Federal Ministry of Health reveal a continuing cost explosion, prompting concerns about the sustainability of the system and potential increases in premiums for the 74 million Germans covered by public health insurance. This situation is placing a growing burden not only on individuals but also on employers, who contribute equally to the cost of coverage.

While the GKV recorded a surplus of 355.9 billion euros in income against 352.4 billion euros in expenditures, this apparent positive balance is misleading. Expenditures grew by 7.8 percent, significantly exceeding the 5.3 percent increase in contributions. Final results for 2025 and the first quarter of 2026 are expected in mid-June, but the trend is clear: the gap between income and expenses is widening. Federal Health Minister Nina Warken has acknowledged that double-digit billion-euro funding gaps are anticipated annually starting in 2027, raising questions about how to stabilize the system and control costs.

The escalating costs are not solely attributable to medical care. A significant portion stems from administrative overhead and, notably, rising salaries for executives within the health insurance funds. This has sparked debate about efficiency and accountability within the system. The situation demands a closer look at where costs are escalating and where savings might be found, a challenge Minister Warken has directly addressed.

Rising Administrative Costs and Executive Compensation

Germany’s statutory health insurance landscape comprises 93 separate funds, each with its own administrative structure. In the previous year, these administrations collectively spent 13.3 billion euros, representing a 12.7 percent increase – approximately 602 million euros – compared to 2024. Within this total, administrative costs rose by 4.4 percent, while personnel costs, including salaries, wages, social security contributions, and pensions, increased by an even more substantial 6 percent. These personnel costs cover employees involved in consulting, application processing, benefit accounting, and member administration.

Adding to the scrutiny, reports indicate significant increases in the compensation of health insurance fund executives. According to a report by Bild, the new CEO of BKK firmus received a salary increase of 31,424 euros compared to their predecessor. BKK firmus currently levies one of the lowest contribution rates in the country. Perhaps more striking, the head of Bahn-BKK saw their remuneration rise from 178,750 euros to 195,000 euros, plus a bonus of 44,688 euros. Bahn-BKK increased its additional contribution by 1.2 percentage points to 3.4 percent at the end of 2025. Similar salary increases were reported for executives at other funds.

Drivers of Healthcare Costs: Hospitals, Outpatient Care, and Pharmaceuticals

Beyond administrative expenses, the largest driver of costs within the GKV remains hospital treatment, accounting for 111.4 billion euros – a 9.7 billion euro increase, or 9.6 percent, compared to 2024. The Federal Ministry of Health noted that this increase was more than double the average annual growth rate between 2013 and 2024. Efforts to address this include concentrating stationary care, specializing services, and integrating ambulatory structures, though the effectiveness of the current hospital reform in achieving these goals remains a point of contention.

Outpatient care costs also saw a significant rise, increasing by 3.8 billion euros, or 7.6 percent. This was driven by increased compensation for contracted physicians and psychotherapists, as well as a substantial increase in ambulatory surgeries (15.7 percent), specialized outpatient treatments (16.3 percent), treatments in university outpatient clinics (8.9 percent), and specialized ambulatory palliative care (15.2 percent), according to the Health Ministry. The Federal Ministry of Health continues to analyze these trends to identify areas for potential cost containment.

Pharmaceuticals represent the second-largest cost driver, nearly matching the expenses for hospital treatments at 58.5 billion euros – a 3.2 billion euro increase, or 5.9 percent. This growth also exceeded the average annual increase between 2013 and 2024. Spending on non-pharmacological treatments, known as “Heilmittel,” also rose sharply, reaching approximately 14.7 billion euros, a 10.4 percent increase year-over-year. These treatments include physiotherapy (557 million euros in 2025) and ergotherapy (439 million euros).

Other significant expenses include medical treatment and nursing care (12 billion euros, a 12.6 percent increase), transportation costs (10.4 billion euros, an 8.9 percent increase), and rehabilitation (5.1 billion euros, a 10 percent increase).

Impact on Insured Individuals and Future Outlook

Despite these rising costs, the general contribution rate for statutory health insurance remains stable at 14.6 percent. However, the additional contribution, which varies by fund, is increasing. The average additional contribution is now 2.9 percent, a notable jump from 2.5 percent in 2025. Insured individuals now pay an average of 17.5 percent of their gross income, split equally between employees and employers. The range of total contributions varies from 16.78 to 19.0 percent.

The financial pressures on the GKV are likely to intensify. Minister Warken has warned of double-digit billion-euro funding gaps expected annually from 2027. Addressing these challenges will require a multifaceted approach, including efforts to improve efficiency, control administrative costs, and potentially re-evaluate the scope of covered services. The ongoing debate surrounding the Krankenhausreform (hospital reform) highlights the complexities involved in restructuring the healthcare system to achieve long-term financial sustainability.

The situation underscores the need for ongoing monitoring of healthcare expenditures and proactive measures to ensure the continued affordability and accessibility of healthcare for all Germans. The interplay between rising costs, executive compensation, and the overall financial health of the GKV will undoubtedly remain a central topic of discussion in German healthcare policy for the foreseeable future.

The next key date to watch is mid-June 2026, when the final results for 2025 and the first quarter of 2026 will be released, providing a more comprehensive picture of the GKV’s financial situation. We encourage readers to share their thoughts and experiences with the German healthcare system in the comments below.